Geron Corporation (Nasdaq:GERN) will announce its financial results for
the 2009 second quarter on Thursday, July 30, 2009, after the closing of
the equity market. Thomas B. Okarma, Ph.D., M.D., Geron’s president and
chief executive officer, and David L. Greenwood, Geron’s executive vice
president and chief financial officer, will host a conference call for
analysts and investors on Friday, July 31 at 8:00 a.m. Pacific Time,
11:00 a.m. Eastern Time.
Participants can access the conference call live via telephone by
dialing 866-788-0544 (U.S.); 857-350-1682 (international). The passcode
is 92419512. A live audio-only webcast is also available through a link
that is posted on the Conferences page in the Investor Relations section
of Geron’s Web site at http://www.geron.com.
The audio Web broadcast of the conference call will be available for
replay through August 28, 2009.
Geron is developing first-in-class biopharmaceuticals for the treatment
of cancer and chronic degenerative diseases, including spinal cord
injury, heart failure and diabetes. The company is advancing an
anti-cancer drug and a cancer vaccine that target the enzyme telomerase
through multiple clinical trials in different cancers and has received
clearance to initiate the first clinical trial of a human embryonic stem
cell (hESC)-based therapy. For more information, visit www.geron.com.
Geron Corporation
Anna Krassowska, Ph.D.
Investor and Media
Relations
650-473-7765
info@geron.com
